Skip to main content

Drug Interactions between cabotegravir and Magsal

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

magnesium salicylate cabotegravir

Applies to: Magsal (magnesium salicylate / phenyltoloxamine) and cabotegravir

ADJUST DOSING INTERVAL: Coadministration with antacids, mineral supplements, or other medications containing polyvalent cations such as magnesium, aluminum, calcium, and iron may decrease the bioavailability of oral cabotegravir. The proposed mechanism involves chelation of cabotegravir by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract. The interaction has not been studied with cabotegravir, but has been reported with other integrase strand transfer inhibitors (INSTIs).

MANAGEMENT: To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of cabotegravir, medications containing polyvalent cations such as antacids and mineral supplements should be administered at least 2 hours before or 4 hours after the oral cabotegravir dose.

References

  1. Cerner Multum, Inc. "Australian Product Information."
  2. Cerner Multum, Inc. (2015) "Canadian Product Information."
  3. US National Library of Medicine (2019) Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions
  4. (2021) "Product Information. Vocabria (cabotegravir)." ViiV Healthcare
View all 4 references

Switch to consumer interaction data

Drug and food interactions

Moderate

phenyltoloxamine food

Applies to: Magsal (magnesium salicylate / phenyltoloxamine)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
View all 4 references

Switch to consumer interaction data

Moderate

magnesium salicylate food

Applies to: Magsal (magnesium salicylate / phenyltoloxamine)

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References

  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.